Table 3. Effectiveness, functionality, and quality of life of PsA patients treated with biological therapy at 12 months.

Adherence patients (n = 147)							Persistents patients (n=142)
Anti-TNF drug	Baseline		12 months		Diff.	p-value	Anti-TNF drug	Baseline		12 months		Diff.	p-value
	mean	SD	mean	SD				mean	SD	mean	SD
CDAI							CDAI
All Anti-TNF	21.86	17.19	11.51	12.65	-10.34	<0.001	All Anti-TNF	21.85	16.87	10.92	12.32	-10.93	<0.001
Adalimumab	21.72	17.42	10.29	11.44	-11.43	<0.001	Adalimumab	22.06	17.07	10.31	11.76	-11.74	<0.001
Etanercept	20.98	16.69	12.04	13.21	-8.94	<0.001	Etanercept	20.12	16.43	9.86	11.49	-10.26	0.001
Infliximab	24.43	17.98	15.66	15.85	-8.77	0.011	Infliximab	24.52	17.36	15.46	15.43	-9.06	0.008
BASDAI							BASDAI
All Anti-TNF	5.00	2.62	2.98	2.29	-2.02	<0.001	All Anti-TNF	4.98	2.58	2.88	2.29	-2.10	<0.001
Adalimumab	4.78	2.53	2.81	2.20	-1.96	<0.001	Adalimumab	4.80	2.52	2.77	2.26	-2.03	<0.001
Etanercept	5.09	2.63	2.91	2.11	-2.19	<0.001	Etanercept	4.97	2.55	2.62	1.95	-2.34	<0.001
Infliximab	5.74	2.98	3.86	2.94	-1.88	<0.001	Infliximab	5.78	2.88	3.85	2.84	-1.93	<0.001
Functionality (HAQ)							Functionality (HAQ)
All Anti-TNF	1.14	0.70	0.77	0.62	-0.36	< 0.001	All Anti-TNF	1.13	0.70	0.74	0.61	-0.39	0.001
Adalimumab	1.10	0.70	0.71	0.57	-0.39	< 0.001	Adalimumab	1.12	0.71	0.68	0.58	-0.44	<0.001
Etanercept	1.17	0.74	0.87	0.65	-0.30	0.003	Etanercept	1.11	0.72	0.78	0.64	-0.32	<0.001
Infliximab	1.24	0.66	0.84	0.74	-0.40	0.003	Infliximab	1.21	0.67	0.87	0.70	-0.34	0.005
Quality of Life (EQ-5D)							Quality of Life (EQ-5D)
All Anti-TNF	0.67	0.19	0.76	0.17	0.09	<0.001	All Anti-TNF	0.66	0.18	0.76	0.17	0.10	<0.001
Adalimumab	0.66	0.18	0.77	0.16	0.10	<0.001	Adalimumab	0.65	0.18	0.77	0.17	0.11	<0.001
Etanercept	0.68	0.18	0.78	0.14	0.10	<0.001	Etanercept	0.67	0.18	0.79	0.13	0.12	<0.001
Infliximab	0.64	0.22	0.68	0.23	0.04	0.177	Infliximab	0.66	0.22	0.69	0.23	0.03	0.268

Diff: difference; SD: Standard deviation